10x Genomics (TXG) Stock Forecast, Price Target & Predictions
TXG Stock Forecast
10x Genomics stock forecast is as follows: an average price target of $30.20 (represents a 79.98% upside from TXG’s last price of $16.78) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.
TXG Price Target
The average price target for 10x Genomics (TXG) is $30.20 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $24.00. This represents a potential 79.98% upside from TXG's last price of $16.78.
TXG Analyst Ratings
According to 9 Wall Street analysts, 10x Genomics's rating consensus is 'Hold'. The analyst rating breakdown for TXG stock is 0 'Strong Buy' (0.00%), 3 'Buy' (33.33%), 5 'Hold' (55.56%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).
10x Genomics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Tejas Savant | Morgan Stanley | $46.00 | $19.65 | 134.10% | 174.14% |
| Jul 23, 2024 | Kyle Mikson | Canaccord Genuity | $32.00 | $18.11 | 76.70% | 90.70% |
| Jul 10, 2024 | Justin Bowers | Deutsche Bank | $25.00 | $18.25 | 36.99% | 48.99% |
| Jun 28, 2024 | Luke Sergott | Barclays | $24.00 | $19.85 | 20.91% | 43.03% |
| Jun 03, 2024 | Tycho Peterson | Jefferies | $24.00 | $22.42 | 7.05% | 43.03% |
| May 01, 2024 | Luke Sergott | Barclays | $36.00 | $29.28 | 22.95% | 114.54% |
| Apr 10, 2024 | Luke Sergott | Barclays | $45.00 | $37.37 | 20.42% | 168.18% |
| Dec 14, 2022 | - | Deutsche Bank | $50.00 | $35.21 | 42.01% | 197.97% |
The latest 10x Genomics stock forecast, released on Aug 13, 2024 by Tejas Savant from Morgan Stanley, set a price target of $46.00, which represents a 134.10% increase from the stock price at the time of the forecast ($19.65), and a 174.14% increase from TXG last price ($16.78).
10x Genomics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $46.00 | $33.14 |
| Last Closing Price | $16.78 | $16.78 | $16.78 |
| Upside/Downside | -100.00% | 174.14% | 97.50% |
In the current month, the average price target of 10x Genomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 10x Genomics's last price of $16.78. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | UBS | Neutral | Neutral | Hold |
| Oct 30, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Oct 30, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 16, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Oct 10, 2024 | UBS | Buy | Buy | Hold |
| Oct 10, 2024 | Stephens | Underperform | Underperform | Hold |
| Sep 03, 2024 | UBS | Buy | Buy | Hold |
| Aug 13, 2024 | UBS | Buy | Buy | Hold |
| Aug 13, 2024 | Jefferies | Underperform | Underperform | Hold |
| Jul 22, 2024 | Jefferies | Hold | Buy | Upgrade |
10x Genomics's last stock rating was published by UBS on Oct 30, 2024. The company gave TXG a "Neutral" rating, the same as its previous rate.
10x Genomics Financial Forecast
10x Genomics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $153.64M | $146.82M | $134.28M | $156.23M | $131.07M | $114.61M | $114.50M | $143.53M | $125.30M | $115.84M | $105.82M | $112.22M | $71.82M | $42.91M | $71.91M | $75.29M | $61.21M |
| Avg Forecast | $192.04M | $182.47M | $171.91M | $163.85M | $172.80M | $161.75M | $152.63M | $143.58M | $153.37M | $156.89M | $150.08M | $142.24M | $182.73M | $151.30M | $139.97M | $128.82M | $148.17M | $128.96M | $115.70M | $113.25M | $148.53M | $122.56M | $112.85M | $102.51M | $100.40M | $61.19M | $32.56M | $73.42M | $70.00M | $54.90M |
| High Forecast | $209.41M | $198.98M | $187.46M | $178.67M | $188.44M | $176.38M | $166.44M | $155.24M | $182.00M | $159.89M | $150.08M | $142.24M | $182.80M | $155.34M | $152.63M | $140.47M | $161.57M | $128.96M | $115.70M | $113.25M | $148.53M | $122.56M | $112.85M | $102.51M | $100.40M | $61.19M | $32.56M | $73.42M | $70.00M | $54.90M |
| Low Forecast | $182.85M | $173.74M | $163.68M | $156.01M | $164.53M | $154.01M | $145.33M | $133.46M | $142.12M | $153.90M | $150.08M | $142.24M | $182.60M | $142.24M | $133.27M | $122.65M | $141.08M | $128.96M | $115.70M | $113.25M | $148.53M | $122.56M | $112.85M | $102.51M | $100.40M | $61.19M | $32.56M | $73.42M | $70.00M | $54.90M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 11 | 5 | 1 | 1 | 3 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.05% | 1.04% | 1.05% | 1.02% | 0.99% | 1.01% | 0.97% | 1.02% | 1.03% | 1.03% | 1.12% | 1.17% | 1.32% | 0.98% | 1.08% | 1.11% |
10x Genomics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $182.73M, with a low forecast of $182.60M, and a high forecast of $182.80M. TXG's average Quarter revenue forecast represents a 18.93% increase compared to the company's last Quarter revenue of $153.64M (Sep 23).
10x Genomics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 11 | 5 | 1 | 1 | 3 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-94.80M | $-63.36M | $-49.63M | $-16.29M | $-39.92M | $-63.72M | $-41.57M | $-8.45M | $-9.15M | $-2.56M | $-4.43M | $-402.89M | $-59.99M | $-34.97M | $-15.92M | $-3.19M | $-6.85M |
| Avg Forecast | $-40.75M | $-38.72M | $-36.48M | $-34.77M | $-36.67M | $-34.33M | $-32.39M | $-30.47M | $-32.55M | $-33.30M | $-31.85M | $-44.78M | $-38.78M | $-32.11M | $-29.70M | $-40.71M | $-6.20M | $-27.37M | $-24.55M | $-32.18M | $-31.52M | $-26.01M | $-23.95M | $-6.35M | $-21.31M | $-12.98M | $-6.91M | $-10.94M | $-14.85M | $-5.13M |
| High Forecast | $-38.80M | $-36.87M | $-34.73M | $-33.11M | $-34.92M | $-32.68M | $-30.84M | $-28.32M | $-30.16M | $-32.66M | $-31.85M | $-35.82M | $-38.75M | $-30.19M | $-28.28M | $-32.57M | $-4.96M | $-27.37M | $-24.55M | $-25.74M | $-31.52M | $-26.01M | $-23.95M | $-5.08M | $-21.31M | $-12.98M | $-6.91M | $-8.75M | $-14.85M | $-4.11M |
| Low Forecast | $-44.44M | $-42.23M | $-39.78M | $-37.92M | $-39.99M | $-37.43M | $-35.32M | $-32.94M | $-38.62M | $-33.93M | $-31.85M | $-53.73M | $-38.79M | $-32.97M | $-32.39M | $-48.85M | $-7.44M | $-27.37M | $-24.55M | $-38.62M | $-31.52M | $-26.01M | $-23.95M | $-7.61M | $-21.31M | $-12.98M | $-6.91M | $-13.12M | $-14.85M | $-6.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.95% | 2.13% | 1.22% | 2.63% | 1.46% | 2.60% | 1.29% | 0.27% | 0.35% | 0.11% | 0.70% | 18.91% | 4.62% | 5.06% | 1.46% | 0.21% | 1.33% |
undefined analysts predict TXG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 10x Genomics's previous annual EBITDA (undefined) of $NaN.
10x Genomics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 11 | 5 | 1 | 1 | 3 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-92.99M | $-62.41M | $-50.75M | $-17.21M | $-41.91M | $-64.46M | $-42.41M | $-18.45M | $-17.17M | $-11.05M | $-11.55M | $-415.57M | $-65.85M | $-40.17M | $-21.14M | $-7.13M | $-9.60M |
| Avg Forecast | $-28.60M | $-31.77M | $-40.04M | $-46.64M | $-29.24M | $-33.14M | $-41.16M | $-46.67M | $-35.23M | $-39.68M | $-57.83M | $-45.69M | $-42.17M | $-55.59M | $-48.24M | $-41.54M | $-13.53M | $-56.05M | $-46.56M | $-32.84M | $-10.37M | $-22.69M | $-31.25M | $-16.56M | $-22.79M | $-36.59M | $-59.79M | $-14.52M | $-15.68M | $-7.20M |
| High Forecast | $-26.82M | $-29.80M | $-37.55M | $-43.74M | $-27.42M | $-31.08M | $-38.60M | $-37.34M | $-18.79M | $-37.21M | $-54.23M | $-36.55M | $-25.77M | $-38.67M | $-45.23M | $-33.23M | $-10.82M | $-56.05M | $-46.56M | $-26.27M | $-10.37M | $-22.69M | $-31.25M | $-13.25M | $-22.79M | $-36.59M | $-59.79M | $-11.62M | $-15.68M | $-5.76M |
| Low Forecast | $-31.96M | $-35.51M | $-44.75M | $-52.12M | $-32.68M | $-37.03M | $-46.00M | $-56.01M | $-46.97M | $-44.35M | $-64.63M | $-54.83M | $-57.40M | $-70.09M | $-53.91M | $-49.84M | $-16.24M | $-56.05M | $-46.56M | $-39.40M | $-10.37M | $-22.69M | $-31.25M | $-19.87M | $-22.79M | $-36.59M | $-59.79M | $-17.43M | $-15.68M | $-8.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.67% | 1.29% | 1.22% | 1.27% | 0.75% | 1.38% | 1.29% | 1.78% | 0.76% | 0.35% | 0.70% | 18.24% | 1.80% | 0.67% | 1.46% | 0.45% | 1.33% |
10x Genomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TXG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
10x Genomics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 11 | 5 | 1 | 1 | 3 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $82.42M | $91.51M | $83.28M | $78.89M | $73.40M | $79.34M | $66.67M | $69.88M | $62.08M | $68.70M | $56.90M | $55.97M | $51.55M | $44.42M | $50.39M | $38.76M | $32.61M |
| Avg Forecast | $109.95M | $104.47M | $98.42M | $93.81M | $98.94M | $92.61M | $87.39M | $82.21M | $87.81M | $89.83M | $85.93M | $71.83M | $104.62M | $86.63M | $80.14M | $65.30M | $51.24M | $73.84M | $66.25M | $51.62M | $85.04M | $70.17M | $64.61M | $81.56M | $57.48M | $35.03M | $18.64M | $34.61M | $40.08M | $24.46M |
| High Forecast | $119.90M | $113.93M | $107.33M | $102.30M | $107.89M | $100.99M | $95.30M | $88.88M | $104.20M | $91.54M | $85.93M | $86.19M | $104.66M | $88.94M | $87.39M | $78.36M | $61.49M | $73.84M | $66.25M | $61.94M | $85.04M | $70.17M | $64.61M | $97.87M | $57.48M | $35.03M | $18.64M | $41.53M | $40.08M | $29.35M |
| Low Forecast | $104.69M | $99.47M | $93.71M | $89.32M | $94.20M | $88.18M | $83.21M | $76.41M | $81.37M | $88.12M | $85.93M | $57.46M | $104.55M | $81.44M | $76.30M | $52.24M | $40.99M | $73.84M | $66.25M | $41.30M | $85.04M | $70.17M | $64.61M | $65.25M | $57.48M | $35.03M | $18.64M | $27.69M | $40.08M | $19.57M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.14% | 1.28% | 1.54% | 0.99% | 1.20% | 1.29% | 0.82% | 0.88% | 1.06% | 0.70% | 0.97% | 1.47% | 2.38% | 1.46% | 0.97% | 1.33% |
10x Genomics's average Quarter SG&A projection for Dec 23 is $104.62M, based on 3 Wall Street analysts, with a range of $104.55M to $104.66M. The forecast indicates a 26.95% rise compared to TXG last annual SG&A of $82.42M (Sep 23).
10x Genomics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 11 | 5 | 1 | 1 | 3 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.79 | $-0.53 | $-0.44 | $-0.15 | $-0.37 | $-0.57 | $-0.38 | $-0.16 | $-0.15 | $-0.10 | $-0.11 | $-3.87 | $-0.65 | $-0.41 | $-0.22 | $-0.07 | $-0.33 |
| Avg Forecast | $-0.24 | $-0.26 | $-0.33 | $-0.39 | $-0.24 | $-0.27 | $-0.34 | $-0.39 | $-0.29 | $-0.33 | $-0.48 | $-0.50 | $-0.35 | $-0.46 | $-0.40 | $-0.37 | $-0.28 | $-0.47 | $-0.39 | $-0.34 | $-0.09 | $-0.19 | $-0.26 | $-0.27 | $-0.19 | $-0.30 | $-0.50 | $-0.13 | $-0.13 | $-0.13 |
| High Forecast | $-0.22 | $-0.25 | $-0.31 | $-0.36 | $-0.23 | $-0.26 | $-0.32 | $-0.31 | $-0.16 | $-0.31 | $-0.45 | $-0.47 | $-0.21 | $-0.32 | $-0.37 | $-0.35 | $-0.26 | $-0.47 | $-0.39 | $-0.34 | $-0.09 | $-0.19 | $-0.26 | $-0.27 | $-0.19 | $-0.30 | $-0.50 | $-0.13 | $-0.13 | $-0.13 |
| Low Forecast | $-0.26 | $-0.29 | $-0.37 | $-0.43 | $-0.27 | $-0.31 | $-0.38 | $-0.46 | $-0.39 | $-0.37 | $-0.54 | $-0.56 | $-0.48 | $-0.58 | $-0.45 | $-0.42 | $-0.31 | $-0.47 | $-0.39 | $-0.34 | $-0.09 | $-0.19 | $-0.26 | $-0.27 | $-0.19 | $-0.30 | $-0.50 | $-0.13 | $-0.13 | $-0.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.72% | 1.33% | 1.18% | 0.54% | 0.79% | 1.47% | 1.13% | 1.85% | 0.79% | 0.38% | 0.40% | 20.39% | 2.13% | 0.82% | 1.66% | 0.54% | 2.63% |
According to undefined Wall Street analysts, 10x Genomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TXG previous annual EPS of $NaN (undefined).
10x Genomics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $2.76 | $39.75 | 1340.22% | Buy |
| BEAM | Beam Therapeutics | $24.36 | $64.20 | 163.55% | Buy |
| GH | Guardant Health | $23.60 | $57.27 | 142.67% | Buy |
| TXG | 10x Genomics | $16.78 | $30.20 | 79.98% | Hold |
| TWST | Twist Bioscience | $42.05 | $42.40 | 0.83% | Buy |
| VCYT | Veracyte | $34.98 | $26.00 | -25.67% | Buy |
TXG Forecast FAQ
Is 10x Genomics a good buy?
No, according to 9 Wall Street analysts, 10x Genomics (TXG) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 33.33% of TXG's total ratings.
What is TXG's price target?
10x Genomics (TXG) average price target is $30.2 with a range of $24 to $46, implying a 79.98% from its last price of $16.78. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will 10x Genomics stock go up soon?
According to Wall Street analysts' prediction for TXG stock, the company can go up by 79.98% (from the last price of $16.78 to the average price target of $30.2), up by 174.14% based on the highest stock price target, and up by 43.03% based on the lowest stock price target.
Can 10x Genomics stock reach $30?
TXG's average twelve months analyst stock price target of $30.2 supports the claim that 10x Genomics can reach $30 in the near future.
What are 10x Genomics's analysts' financial forecasts?
10x Genomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $630.77M (high $686.5M, low $597.33M), average EBITDA is $-134M (high $-127M, low $-146M), average net income is $-150M (high $-134M, low $-172M), average SG&A $361.15M (high $393.06M, low $342M), and average EPS is $-1.244 (high $-1.113, low $-1.422). TXG's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $710.26M (high $774.52M, low $676.27M), average EBITDA is $-151M (high $-144M, low $-164M), average net income is $-147M (high $-138M, low $-164M), average SG&A $406.66M (high $443.45M, low $387.2M), and average EPS is $-1.218 (high $-1.142, low $-1.361).
Did the TXG's actual financial results beat the analysts' financial forecasts?
Based on 10x Genomics's last annual report (Dec 2022), the company's revenue was $516.41M, beating the average analysts forecast of $506.09M by 2.04%. Apple's EBITDA was $-161M, beating the average prediction of $-90.3M by 78.84%. The company's net income was $-166M, beating the average estimation of $-149M by 11.43%. Apple's SG&A was $298.3M, beating the average forecast of $242.95M by 22.78%. Lastly, the company's EPS was $-1.46, missing the average prediction of $-1.468 by -0.58%. In terms of the last quarterly report (Sep 2023), 10x Genomics's revenue was $153.64M, beating the average analysts' forecast of $151.3M by 1.55%. The company's EBITDA was $-94.795M, beating the average prediction of $-32.109M by 195.23%. 10x Genomics's net income was $-92.986M, beating the average estimation of $-55.587M by 67.28%. The company's SG&A was $82.42M, missing the average forecast of $86.63M by -4.86%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.46 by 71.59%